Exhibit
10.20


 


Amendment
of


 


the


Convertible Loan Agreement


 


“Amendment”


 


of


 





 



 


between


 


	NLS
    Pharmaceutics AG	 	 
	Alter
    Postplatz 2	 	 
	6370
    Stans	 	 
	Switzerland	 	 
	 	 	“Borrower”
	 	 	 
	 	 	 
	 	 	 
	 	and	 
	 	 	 
	 	 	 
	 	 	 
	Alexander
    Zwyer	 	 
	Steinwichslenstrasse
    9	 	 
	9052
    Niederteufen	 	 
	Switzerland	 	"Lender"
	 	 	 
	 	 	 
	 	 	 
	 	 	(Borrower
and Lender each a ʺPartyʺ
	 	 	collectively
    the ʺPartiesʺ)
	 	 	 
	 	 	 
	 	 	 
	 	regarding	 
	 	reduction
    of loan amount	 



 






     

     


    




	Amendment	2/3



 


WHEREAS


 


	 	A.	The
    Borrower is a stock corporation (Aktiengesellschaft) in accordance with Swiss law with its registered seat and principal
    place of business at Stans (company number CHE-447.067.367). The Borrower has a share capital of CHF 139’200.00, divided
    into 1’392 registered shares with a nominal value of CHF 100.00 each, which have been fully paid in.


 


	 	B.	The
    Lender and the Borrower entered into a convertible loan agreement dated 21 February 2020 (“Agreement”)
    as attached hereto. The Lender agreed to make available to the Borrower a convertible loan in the amount of CHF 150’000.00
    (“Loan Amount”).


 


	 	C.	The
    Lender granted to the Borrower CHF 100’000.00 of the Loan Amount. Therefore, CHF 50’000.00 of the Loan Amount
    are still outstanding (“Outstanding Loan Amount”).


 


	 	D.	According
    to Section 10.6 of the Agreement the Agreement cannot be amended, supplemented, modified or waived except by a written instruments
    signed in advance by all Parties. Therefore, the Parties have entered into this Amendment.


 


NOW,
THEREFORE, the Parties agree as follows:


 


Any
capitalized terms, if not defined otherwise in this Amendment, shall have the meaning as set forth in the Agreement.


 


	1.	Reduction
    of the Loan Amount


 


The
Parties agree to reduce the Loan Amount by the Outstanding Loan Amount. To this end, the Borrower hereby and irrevocably waives
its right to claim from the Lender the payment of the Outstanding Loan Amount. The Lender is therefore not obligated to pay the
second tranche as stated in Section 1 of the Agreement.


 


	2.	Remaining
    Provisions


 


Except
for the amendments provided herein, all remaining provisions of the Agreement shall remain unchanged and binding for the Parties.


 


This
Amendment shall form an integral part of the Agreement.


 


	3.	Governing
    Law and Jurisdiction


 


This
Amendment shall be governed by and construed in accordance with the substantive laws of Switzerland, without reference to principles
of conflict of laws or choice of laws.


 


All
disputes arising out of or in connection with the Amendment, including disputes on its conclusion, binding effect, amendment and
termination, shall be resolved by the ordinary courts of Zurich, canton of Zurich, Switzerland, venue being Zurich 1.


 


[signature
page to follow]


 






     

     


    




	Amendment	3/3


 




	Borrower
    	 	 
	NLS Pharmaceutics AG	 	 
	 	 	 
	/s/
Ronald Hafner	 	/s/ Alexander Zwyer

	Name: Ronald Hafner	 	Name:
    Alexander Zwyer
	Function: Chairman of the Board	 	Function: CEO
	 	 	 
	 	 	 
	Lender	 	 
	 	 	 
	/s/ Alexander Zwyer
	 	 
	Alexander Zwyer	 	 
	 	 	 


 


Attachment:Convertible
Loan Agreement dated 21 February 2020